Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30038735HIVENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TVIS20018682HPVENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TVIS20034843HPVENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TVIS44012427HTLV-1ENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TVIS44023718HTLV-1ENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TVIS44051116HTLV-1ENSG00000169032.11protein_codingMAP2K1YesNo5604A4QPA9
B4DFY5
Q02750
TCGA Plot Options
Drug Information
GeneMAP2K1
DrugBank IDDB08911
Drug NameTrametinib
Target IDBE0000870
UniProt IDQ02750
Regulation Typeinhibitor
PubMed IDs23432625; 23971497
CitationsSalama AK, Kim KB: Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23.@@Ho MY, Morris MJ, Pirhalla JL, Bauman JW, Pendry CB, Orford KW, Morrison RA, Cox DS: Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica. 2014 Apr;44(4):352-68. doi: 10.3109/00498254.2013.831143. Epub 2013 Aug 23.
GroupsApproved
Direct ClassificationPyridopyrimidines
SMILESCN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
Pathways
PharmGKBPA166115364
ChEMBLCHEMBL2103875